Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hyland's Argues Class Action Trips On State Laws Despite 'Artful Pleading'

This article was originally published in The Tan Sheet

Executive Summary

Hyland’s says a class action complaint alleging deceptive business practices and false advertising for its baby products is not suitable to represent a class of consumers outside New York. But the plaintiffs argue that the issue over class suitability should be considered during the certification stage.

You may also be interested in...



Hyland’s Score Points Asking To Dismiss Class Action, But Loses Ruling

Hyland’s fails to convince a federal court to dismiss nationwide class claims alleging false advertising of its baby products, but the judge says the two women alleging the firm made false claims about its homeopathic formulas have a “high hurdle” to demonstrate a nationwide class action.

Hyland’s Score Points Asking To Dismiss Class Action, But Loses Ruling

Hyland’s fails to convince a federal court to dismiss nationwide class claims alleging false advertising of its baby products, but the judge says the two women alleging the firm made false claims about its homeopathic formulas have a “high hurdle” to demonstrate a nationwide class action.

Homeopathic Regulatory Evaluation Stocked With FDA Concerns, Industry Answers

The industry wants FDA to consider that a fraction of poison control reports are for homeopathics compared to other drugs and the agency’s current enforcement authorities maintain compliance in manufacturing and marketing the products. FDA is considering whether to maintain its policy that recognizes an ingredient’s inclusion in the HPUS monograph as pre-market approval.

Related Content

Topics

UsernamePublicRestriction

Register

PS108257

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel